Erlotinib HCl CAS183319-69-9 CAS NO.183319-69-9

Product Details

our advantage:

1. best quality in your requirement

2. competitive price in china market

3. mature technical support

4. professional logistic support

5 . full experience of large numbers containers loading in chinese sea port

6. fast shipment by reputed shipping line

7. packing with pallet as buyer's special request

8. best service after shipment with e mail

9. cargoes together with container after-sales service available

10. full experience in export

11. raw materials from chinese origin

all we want is win-win business. send yr. inquiries, you will get it !

cas no.	183319-69-9
	erlotinib hcl

	c22h23n3o4.hcl
	429.9
	98%
	can supply large quantity in kgs scale
alias	tarceva;cp-358774;cp 358774;cp358774;osi-774;osi 774;osi774;nsc-718781;nsc 718781;nsc718781
product brief introduction	erlotinib is a directly acting inhibitor of human egfr tyrosine kinase with an ic50 of 2 nm.
detailed description:	erlotinib hcl potently inhibits egfr activation in intact cells including hns human head and neck tumor cells (ic50 20nm), difi humancolon cancer cells andmda mb-468 human breast cancer cells. erlotinib hcl (1 μm) induces apoptosis in difi humancolon cancer cells.erlotinib inhibits growth of a panel of nsclc cell lines including a549, h322, h3255, h358 h661, h1650, h1975, h1299, h596 with ic50 ranging from 29 nm to >20 μm.erlotinib hcl(2 μm) significantly inhibits growth of aspc-1 and bxpc-3 pancreatic cells.the effects of erlotinib hcl in combination with gemcitabine are considered additive in kras-mutated pancreatic cancer cells. ten micromolar of erlotinib hcl inhibits egfr phospho-rylation at the y845 (src-dependent phosphorylation) and y1068 (auto-phosphorylation) sites. combination with erlotinib hcl could down-modulate rapamycin-stimulated akt activity and produces a synergistic effect on cell growth inhibition.